Grants Funded
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
Degradable Orthopedic Devices to Modulate Healing
Principal Investigator
Samuel Lin MD
Samuel Lin MD
Year
2013
2013
Institution
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
Funding Mechanism
National Endowment for Plastic Surgery Grant
National Endowment for Plastic Surgery Grant
Focus Area
Cranio/Maxillofacial/Head and Neck
Cranio/Maxillofacial/Head and Neck
Abstract
Degradable orthopedic plates and screws are available, but major clinical limitations exist which include osteolysis, sterile sinus formation, incomplete remodeling of the bone, and improper dynamics between device strength retention and wound healing. Furthermore, these screws are typically only used in pediatric patients due to lower intrinsic strength. We propose the use of degradable silk protein-based orthopedic devices (screws and plates) to overcome these limitations. The hypothesis is that silk-based screws and plates can provide osseous synthesis following fracture repair, fully degrade in a prescribed time frame, and proactively deliver therapeutic local agents to improve rates of integration, reduce infection and promote healing without requiring surgical removal. Based on extensive Preliminary Data, silk polymeric biomaterials provide mechanical properties to match conventional orthopedic fracture repair while also providing sustained release of therapeutic compounds and tunable degradation lifetimes. The outcome of the planned studies will be an entirely new and innovative set of orthopedic devices that provide: (a) a mechanical match to tissues during repair to avoid stress shielding, (b) full degradation over a six month time frame to allow regeneration by native tissue structure and function, (c) degradation to non inflammatory products – amino acids, and (c) release of antibiotics, anti-inflammatory and osteogenic factors to improve the rate of bone repair and improve surgical recovery. To address these outcomes, we will pursue three aims, materials optimization (Aim 1), in vitro assessment of function (Aim 2), and in vivo assessment of function (Aim 3). An interdisciplinary team of scientists and clinicians will address the needs. The team has assembled strong preliminary data to support the goals of the study.
Degradable orthopedic plates and screws are available, but major clinical limitations exist which include osteolysis, sterile sinus formation, incomplete remodeling of the bone, and improper dynamics between device strength retention and wound healing. Furthermore, these screws are typically only used in pediatric patients due to lower intrinsic strength. We propose the use of degradable silk protein-based orthopedic devices (screws and plates) to overcome these limitations. The hypothesis is that silk-based screws and plates can provide osseous synthesis following fracture repair, fully degrade in a prescribed time frame, and proactively deliver therapeutic local agents to improve rates of integration, reduce infection and promote healing without requiring surgical removal. Based on extensive Preliminary Data, silk polymeric biomaterials provide mechanical properties to match conventional orthopedic fracture repair while also providing sustained release of therapeutic compounds and tunable degradation lifetimes. The outcome of the planned studies will be an entirely new and innovative set of orthopedic devices that provide: (a) a mechanical match to tissues during repair to avoid stress shielding, (b) full degradation over a six month time frame to allow regeneration by native tissue structure and function, (c) degradation to non inflammatory products – amino acids, and (c) release of antibiotics, anti-inflammatory and osteogenic factors to improve the rate of bone repair and improve surgical recovery. To address these outcomes, we will pursue three aims, materials optimization (Aim 1), in vitro assessment of function (Aim 2), and in vivo assessment of function (Aim 3). An interdisciplinary team of scientists and clinicians will address the needs. The team has assembled strong preliminary data to support the goals of the study.
Biography
Samuel J. Lin, MD, MBA, FACS is the program director for the BIDMC/Harvard Plastic Surgery Residency Training Programs, Co-Director for the Harvard Aesthetic and Reconstructive Fellowship Program at BIDMC, and Director of Aesthetic Surgery at BIDMC. Dr. Lin received his Bachelor's degree in Biomedical Engineering from Northwestern University and his MD from Northwestern University Feinberg School of Medicine. He completed his residency in Otolaryngology-Head and Neck Surgery at Northwestern Memorial Hospital, followed by a residency in Plastic and Reconstructive Surgery and microvascular fellowship at M.D. Anderson Cancer Center. Dr. Lin is a member of the American Society of Plastic Surgeons, American Board of Plastic Surgery, and American Association of Plastic Surgeons, as well as a fellow of the American College of Surgeons.
Samuel J. Lin, MD, MBA, FACS is the program director for the BIDMC/Harvard Plastic Surgery Residency Training Programs, Co-Director for the Harvard Aesthetic and Reconstructive Fellowship Program at BIDMC, and Director of Aesthetic Surgery at BIDMC. Dr. Lin received his Bachelor's degree in Biomedical Engineering from Northwestern University and his MD from Northwestern University Feinberg School of Medicine. He completed his residency in Otolaryngology-Head and Neck Surgery at Northwestern Memorial Hospital, followed by a residency in Plastic and Reconstructive Surgery and microvascular fellowship at M.D. Anderson Cancer Center. Dr. Lin is a member of the American Society of Plastic Surgeons, American Board of Plastic Surgery, and American Association of Plastic Surgeons, as well as a fellow of the American College of Surgeons.